KFA Private Wealth Group LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 8.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,037 shares of the company’s stock after purchasing an additional 482 shares during the quarter. KFA Private Wealth Group LLC’s holdings in Johnson & Johnson were worth $936,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. GW&K Investment Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at about $35,000. Dark Forest Capital Management LP increased its stake in shares of Johnson & Johnson by 1,044.4% during the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after purchasing an additional 188 shares during the last quarter. Ruedi Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $42,000. Kepos Capital LP purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $45,000. Finally, VitalStone Financial LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $52,000. Institutional investors own 67.57% of the company’s stock.
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $173.85 on Friday. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. The company’s 50-day moving average is $164.90 and its 200 day moving average is $161.25. The stock has a market capitalization of $451.83 billion, a P/E ratio of 35.19, a P/E/G ratio of 2.89 and a beta of 0.54.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be paid a $1.19 dividend. The ex-dividend date is Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.74%. Johnson & Johnson’s dividend payout ratio is presently 96.36%.
Analysts Set New Price Targets
JNJ has been the subject of several research analyst reports. TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Citigroup assumed coverage on shares of Johnson & Johnson in a report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price objective for the company. Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Barclays raised their price objective on shares of Johnson & Johnson from $171.00 to $175.00 and gave the stock an “equal weight” rating in a report on Monday, July 24th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $187.00 price objective on shares of Johnson & Johnson in a report on Friday, July 21st. Eight research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $171.80.
Check Out Our Latest Research Report on JNJ
Insider Activity
In other news, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at $10,549,440. The disclosure for this sale can be found here. Insiders sold 47,163 shares of company stock valued at $7,928,856 over the last three months. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Energy and Oil Stocks Explained
- MarketBeat Week in Review – 8/7 – 8/11
- How to Invest in Renewable Energy
- 3 Retailers To Watch Closely Next Week
- How to Invest in Biotech Stocks
- Investing in Coffee: 3 Great Strategies to Consider
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
